Raymond James & Associates
CTSO icon

Raymond James & Associates’s Cytosorbents Corp CTSO Stock Holding History

Raymond James & Associates’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$75K Hold
2,500
– – ﹤0.01% 3813
2024
Q2 		$35.2K Hold
2,500
– – ﹤0.01% 3828
2024
Q1 		$47.5K Hold
2,500
– – ﹤0.01% 3807
2023
Q4 		$55.5K Buy
+2,500
New +$74.3K ﹤0.01% 3697
2022
Q2 		– Sell
-4,325
Closed -$276K – 4055
2022
Q1 		$276K Hold
4,325
– – ﹤0.01% 3466
2021
Q4 		$362K Hold
4,325
– – ﹤0.01% 3327
2021
Q3 		$702K Hold
4,325
– – ﹤0.01% 2816
2021
Q2 		$653K Sell
4,325
-6,578
-60% -$1.11M ﹤0.01% 2888
2021
Q1 		$1.89M Buy
10,903
+13
+0.1% +$2.48K ﹤0.01% 2056
2020
Q4 		$1.74M Sell
10,890
-25
-0.2% -$4.18K ﹤0.01% 1977
2020
Q3 		$1.74M Sell
10,915
-75
-0.7% -$13.5K ﹤0.01% 1841
2020
Q2 		$2.18M Hold
10,990
– – ﹤0.01% 1685
2020
Q1 		$1.7M Buy
10,990
+3,825
+53% +$386K ﹤0.01% 1662
2019
Q4 		$552K Sell
7,165
-3,825
-35% -$334K ﹤0.01% 2652
2019
Q3 		$1.11M Buy
10,990
+2,550
+30% +$297K ﹤0.01% 2141
2019
Q2 		$1.12M Hold
8,440
– – ﹤0.01% 2148
2019
Q1 		$1.28M Hold
8,440
– – ﹤0.01% 2051
2018
Q4 		$1.36M Buy
8,440
+975
+13% +$194K ﹤0.01% 1894
2018
Q3 		$1.93M Sell
7,465
-915
-11% -$229K ﹤0.01% 1832
2018
Q2 		$1.91M Buy
8,380
+25
+0.3% +$4.73K ﹤0.01% 1773
2018
Q1 		$1.18M Buy
8,355
+3,355
+67% +$507K ﹤0.01% 2016
2017
Q4 		$650K Buy
5,000
+2,500
+100% +$318K ﹤0.01% 2383
2017
Q3 		$310K Hold
2,500
– – ﹤0.01% 2770
2017
Q2 		$215K Buy
2,500
+1,228
+97% +$108K ﹤0.01% 2937
2017
Q1 		$114K Sell
1,272
-2,000
-61% -$224K ﹤0.01% 3051
2016
Q4 		$357K Sell
3,272
-1,250
-28% -$137K ﹤0.01% 2534
2016
Q3 		$579K Sell
4,522
-11,708
-72% -$1.22M ﹤0.01% 2170
2016
Q2 		$1.48M Buy
16,230
+12,352
+319% +$1.08M ﹤0.01% 1507
2016
Q1 		$304K Buy
+3,878
New +$337K ﹤0.01% 2320
2015
Q4 		– Sell
-6,410
Closed -$809K – 2337
2015
Q3 		$809K Buy
+6,410
New +$855K ﹤0.01% 1700

Other funds holding CTSO

Avenir Corporation
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Raymond James & Associates's CTSO Position: Q3 2024 in Review

Raymond James & Associates held its Cytosorbents Corp (CTSO) position steady in Q3 2024 at 2,500 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

Raymond James & Associates first reported a position in CTSO in Q3 2015 and has held it in 30 quarters since. The position peaked at $2.18M in Q2 2020. 52 funds tracked by Wall St. Rank hold CTSO as of Q3 2024.

  • Raymond James & Associates held 2,500 shares of Cytosorbents Corp worth $75K as of Q3 2024.
  • Raymond James & Associates left its Cytosorbents Corp share count unchanged in Q3 2024.
  • Cytosorbents Corp made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3813 holding.
  • Raymond James & Associates first reported a position in Cytosorbents Corp in Q3 2015 and has held it in 30 quarters since.
  • Raymond James & Associates's Cytosorbents Corp position peaked at $2.18M in Q2 2020.
  • 52 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.